TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leishmaniasis
Researchers from Banaras Hindu University discuss findings in leishmaniasis
June 30th, 2009
According to recent research from Varanasi, India, "Amphotericin B deoxycholate is used as a first-line drug for visceral leishmaniasis (VL) in India. Its major drawbacks are prolonged hospitalization of treated patients and toxicity." "An open label phase 11 study with preformed amphotericin B lipid emulsion (ABLE) was conducted to evaluate safety and efficacy of four regimens of 15 mg/kg each administered in 1-2 doses. Regimen 1 was 7.5 mg/kg/day on day 1 and day 3, and regimen 4 was a single bolus infusion of 1.5 mg/kg. The safety profile was excellent with mild infusion reaction's seen in 38% of the patients. Definitive cure was achieved in 100% of the patients...
Source: TB & Outbreaks Week (2009-06-30)
|
